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Introduction: Acute Kidney Injury (AKI) biomarker utility depends on sample timing after the onset of renal injury.
We compared biomarker performance on arrival in the emergency department (ED) with subsequent performance
in the intensive care unit (ICU).
Methods: Urinary and plasma Neutrophil Gelatinase-Associated Lipocalin (NGAL), and urinary Cystatin C (CysC),
alkaline phosphatase, γ-Glutamyl Transpeptidase (GGT), α- and π-Glutathione S-Transferase (GST), and albumin were
measured on ED presentation, and at 0, 4, 8, and 16 hours, and days 2, 4 and 7 in the ICU in patients after cardiac
arrest, sustained or profound hypotension or ruptured abdominal aortic aneurysm. AKI was defined as plasma
creatinine increase ≥26.5 μmol/l within 48 hours or ≥50% within 7 days.
Results: In total, 45 of 77 patients developed AKI. Most AKI patients had elevated urinary NGAL, and plasma NGAL
and CysC in the period 6 to 24 hours post presentation. Biomarker performance in the ICU was similar or better
than when measured earlier in the ED. Plasma NGAL diagnosed AKI at all sampling times, urinary NGAL, plasma and
urinary CysC up to 48 hours, GGT 4 to 12 hours, and π-GST 8 to 12 hours post insult. Thirty-one patients died or
required dialysis. Peak 24-hour urinary NGAL and albumin independently predicted 30-day mortality and dialysis;
odds ratios 2.87 (1.32 to 6.26), and 2.72 (1.14 to 6.48), respectively. Urinary NGAL improved risk prediction by 11%
(IDIevent of 0.06 (0.002 to 0.19) and IDInon-event of 0.04 (0.002 to 0.12)).
Conclusion: Early measurement in the ED has utility, but not better AKI diagnostic performance than later ICU
measurement. Plasma NGAL diagnosed AKI at all time points. Urinary NGAL best predicted mortality or dialysis
compared to other biomarkers.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12610001012066. Registered 12
February 2010Introduction
Reliance on plasma creatinine delays acute kidney injury
(AKI) diagnosis [1,2]. Novel injury biomarkers may
enable earlier diagnosis. However, biomarker performance
also depends on the interval between insult and time of
measurement [3,4]. In the trial, early intervention in acute
renal failure (EARLYARF) [5], triaging to intervention
within 6 h of admission to the ICU by the urinary tubular
enzymes, alkaline phosphatase (AP) and γ-Glutamyl
Transpeptidase (GGT) resulted in many false negatives.
This occurred because this combination of biomarkers had
a short temporal profile with peak urinary concentrations* Correspondence: zoltan.endre@unsw.edu.au
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unless otherwise stated.before 12 h after injury and the window of opportunity for
diagnosis had been exceeded in many subjects, despite
rapid processing in the ICU. Apart from one study of
plasma and urinary cystatin C [6] little is known about the
temporal profiles of candidate AKI biomarkers of patients
presenting to the emergency department (ED). While
studies have examined biomarker diagnostic performance
in the ED [7,8], subsequent performance at later time points
has not been assessed.
We evaluated the temporal profile of plasma creatinine
and AKI biomarkers in high-risk critically ill patients, who
presented soon after a probable hypoperfusion insult to the
kidney. The temporal profiles of biomarker performance in
AKI diagnosis and mortality prediction were investigated.
We hypothesised that earlier measurement (in the ED)d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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urement in the ICU.
Methods
The EDAKI study was a prospective observational
study investigating the utility of plasma and urinary
biomarkers from admission to the ED throughout the
ICU stay, in patients at high risk of developing AKI. The
study was approved by The Upper South A Regional
Ethics Committee (URA/09/09/062) and registered under
the Australian and New Zealand Clinical Trials Registry
(ACTRN12610001012066) and adhered to the Declaration
of Helsinki. Patients included were admitted to the ICU at
Christchurch Hospital following cardiac arrest, sustained
or prolonged hypotension or probable ruptured abdom-
inal aortic aneurysm (AAA). Sustained hypotension was
defined as systolic blood pressure <90 mmHg or mean ar-
terial pressure <65 mmHg for 60 minutes after 1 L of
intravenous fluid. Profound hypotension was defined
as systolic blood pressure <60 mmHg of any duration.
Exclusion criteria were: under 16 years old, moribund (not
expected to survive 24 h), likely to be discharged within
24 h, drug overdose, treatment limitation order, absent
urinary catheter within 4 h of ED admission, already on
dialysis, longer than 4 h since admission to the ED, or
patients having had inter-hospital transfer unless arrival
in the ED occurred less than 3 h after the initiating
event, and the patients had not already been admitted
to the ICU. Informed consent was obtained from pa-
tients, or a family member. Here we present the primary
analysis of this study. Partial results for some patients
(after cardiac arrest) have been published previously to
illustrate an analysis of combining volume and creatin-
ine kinetics [9].
First urine samples were collected during urinary
catheterisation in the ED. Routine plasma samples
taken on presentation to the ED were retrieved for
additional assay. Both plasma and urine samples were
collected upon admission to the ICU, and at 4, 8, and 16 h
post ICU admission, and at 2, 4, and 7 days. Plasma samples
were assayed for creatinine, neutrophil gelatinase-associated
lipocalin (NGAL) and cystatin C (CysC), and urine samples
were assayed for alkaline phosphatase (AP), γ-glutamyl trans-
peptidase (GGT), NGAL, α- and π-glutathione S-transferase
(GST), CysC, and albumin. Plasma and urinary creatinine
were measured by the Jaffe reaction on an Architect c8000
analyzer using Abbott reagents (Abbott Laboratories,
Abbott Park, IL, USA). Urinary AP was measured by
p-nitrophenol rate reactions and GGT by γ-glutamyl-
p-nitroanilide rate on the Architect c8000 analyzer using
Abbott reagents (Abbott Laboratories, Abbott Park, IL,
USA). Urinary α-GST and π-GST assays were performed
by Argutus Medical using enzyme immunoassays (Argutus
Medical Alpha GST EIA-BIO-91 and Pi GST EIA-BIO85,Argutus Medical, Dublin, Ireland). Plasma NGAL was
analysed using the Triage® NGAL test (Biosite, San
Diego, CA, USA). Urinary NGAL was analysed using
The Architect Urine NGAL assay (Abbott Diagnostic,
Wiesbaden, Germany). Plasma and urinary CysC were
measured on a BNII nephelometer (Dade Behring, GmbH,
Marburg, Germany) by particle-enhanced nephelometric
immunoassay. For AKI outcomes biomarkers were not
normalised to urinary creatinine as we have previously
shown that for AKI outcomes normalisation reduces the
area under the receiver operator characteristic curve
(AUC) [10]. Conversely, we showed that for mortality and
need for dialysis outcomes normalisation to urinary
creatinine improves the AUC, therefore, for the prediction
of mortality and dialysis outcomes, we normalised the
urinary biomarkers to urinary creatinine.
For each patient, the time of commencing renal hypo-
perfusion was adjudicated from the time of the ambulance
call (for cardiac arrest), or when symptoms of severe
shock, such as mental obtundation or hypotension, were
documented (for hypotension), or the time of onset of
abdominal pain (for suspected ruptured AAA). Baseline
plasma creatinine was determined from a chart review,
according to the hierarchy: (1) pre-admission creatinine
within 7 days to 1 year prior to hospital admission; (2)
creatinine at 30-day follow up; (3) hospital discharge
creatinine; and (4) creatinine value on admission. AKI
was diagnosed using the plasma creatinine criteria,
kidney disease improving global outcomes (KDIGO):
an increase of more than 26.5 μmol/l (0.3 mg/dl)
within 48 h, or a relative increase of more than 50%
above baseline within 7 days of admission [11]. Urine
output was not used to classify AKI because it was
not measured during the early course of the disease
in the ED and because of its poor prognostic ability
for meaningful clinical outcomes [12,13]. Severity of
illness was assessed in each patient during the first
24 h of admission using the acute physiological and
chronic health evaluation II (APACHE II) [14]. For
the prediction of mortality and dialysis we used the
maximum normalised urinary biomarker concentration
within 24 h and we evaluated their AKI status during this
time (AKI24), using as baseline creatinine the pre-admission
baseline creatinine where it was known, or the first creatin-
ine measurement in the ED. In this way the prediction is
based on clinically relevant variables.
Statistical analysis
Results were presented as mean ± SD for parametric or
median (interquartile range) for non-parametric variables.
For continuous variables, differences in two variables were
analysed using the independent t-test for parametric, or
Mann-Whitney U-test for non-parametric variables. Dif-
ferences between three or more variables were determined
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transformation where appropriate. Repeated-measures
ANOVA was used to compare repeated series of measure-
ments between groups. The multiple imputation technique
was used to generate possible values for missing data prior
to analysis by repeated-measures ANOVA. Post hoc
Fisher’s least significant difference (LSD) analysis was
performed for all associations with a P-value <0.05 on
ANOVA. For categorical variables, differences in propor-
tions were analysed using the Chi-square test or Fisher’s
exact test when the sample size was small.
Although an exploratory study, we based the sample size
on a power calculation using data from the Early interven-
tion in Acute Renal Failure (EARLYARF) study, in which
the false negative rate of the biomarker (GGT×AP >46.3)
for detecting AKI was 61%. We determined that, assuming
the same AKI incidence rate, 100 patients would provide
85% power at an alpha of 0.05 to detect a false negative
rate reduction of 60%. Because of how we selected the
cohort we expected a higher AKI incidence rate.
The diagnostic, predictive or prognostic performance
of biomarkers was assessed by the AUC. The AUCs were
compared by the DeLong method [15]. Multivariable
logistic regression was used to calculate odds ratios
(ORs) after adjusting for covariates. Variables were included
in the multivariable model if the P-value was <0.1 on
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Figure 1 Patient flow and numbers.to a reference model (comprising variables other than the
biomarker identified with P <0.1 on univariate analysis) to
predict mortality or dialysis was further assessed by
the integrated discrimination improvement (IDI) and
risk assessment plots [16-18]. The AUC, OR, hazard ratio
(HR), and IDI are presented with 95% confidence intervals.
Statistical analysis was performed using PASW® version
18.0 (IBM, Somers, NY, USA), PRISM 5.0® (Graph Pad, La
Jolla, CA, USA), and MatLab 2011b (MathWorks, Natick,
MA, USA).
Results
Between 24 March 2010 and 29 February 2012, 109
patients were recruited. Fifteen patients were excluded
because they were not admitted to the ICU. In the
ICU, another 17 patients were excluded: 3 did not fit
the inclusion criteria, 6 were not expected to survive
24 h, 1 underwent an inter-hospital transfer, 1 a drug
overdose, 2 refused to give consent and 4 had no
samples taken in the ICU because of clinical priorities
(Figure 1). Thus, 77 patients were included in the
analysis: 49 (64%) after cardiac arrest, 22 (29%) after
sustained hypotension (14 secondary to septic shock),
5 (7%) with ruptured AAA, and one with profound
hypotension. Baseline characteristics are presented in
Table 1. A total of 45 patients (58%) developed AKI.
There were no differences in the demographic profile- Not admitted to ICU (n=15)
32)
- Did not meet inclusion criteria (n = 3)
- Not followed up in ICU  (n = 4)
- Inter-hospital transfer after 4h (n = 1)
- Drug overdose (n = 1)
- Moribund (n=6)
- Refused consent (n=2)
51)
rvival
Table 1 Demographic profiles and clinical characteristics
Variables All patients No acute kidney injury Acute kidney injury P-value
(n =77) (n =32) (n =45)
Age, years 62 ± 16 62 ± 17 62 ± 15 0.90
Gender, male 57 (74.0) 25 (78.1) 32 (71.1) 0.49
Ethnicity 0.23
- New Zealand European 61 (81.8) 29 (90.6) 34 (75.6)
- Maori 9 (11.7) 3 (9.4) 6 (13.3)
- Asian 1 (1.3) 0 (0) 4 (8.9)
- Others 4 (5.2) 0 (0) 1 (2.2)
Weight, kg 80 ± 17 80 ± 13 80 ± 20 0.97
Height, cm 171 ± 10 170 ± 8 171 ± 11 0.99
APACHE II score 19 ± 5 19 ± 5 20 ± 5 0.32
Baseline plasma creatinine, μmol/L 92 (74 to 107) 93 (83 to 104) 88 (70 to 109) 0.21
Baseline creatinine selection 0.28
- Pre-hospital (7 to 365 days) 43 (55.8) 17 (53.1) 26 (57.8)
- 30-day follow up 18 (23.4) 8 (25.0) 10 (22.2)
- Hospital final 13 (16.9) 7 (21.8) 6 (13.4)
- First Emergency Department 3 (3.9) 0 (0) 3 (6.7)
Inclusion criteria 0.01
- Cardiac arrest 49 (63.6) 27 (84.4) 22 (48.9)
- Sustained hypotension 22 (28.6) 5 (15.6) 17 (37.8)
- Ruptured abdominal aortic aneurysm 5 (6.5) 0 (0) 5 (11.1)
- Profound hypotension 1 (1.3) 0 (0) 1 (2.2)
Baseline comorbidities
- Hypertension 26 (33.8) 13 (40.6) 13 (28.9) 0.28
- Congestive cardiac failure 7 (9.1) 3 (9.4) 4 (8.9) 0.94
- Ischaemic heart disease 21 (27.3) 11 (34.4) 10 (22.2) 0.24
- Other cardiac diseases 18 (23.4) 8 (25.0) 10 (22.2) 0.78
- Chronic obstructive airways disease 5 (6.5) 1 (3.1) 4 (8.9) 0.31
- Asthma 6 (7.8) 2 (6.2) 4 (8.9) 0.67
- Cerebral vascular accident 13 (16.9) 7 (21.9) 6 (13.3) 0.32
- Diabetes mellitus 11 (14.3) 4 (12.5) 7 (15.6) 0.71
- Kidney impairment 6 (7.8) 4 (12.5) 2 (4.4) 0.19
- Thyroid disease 4 (5.3) 3 (9.4) 1 (2.2) 0.16
- Malignancy 6 (7.8) 3 (9.4) 3 (6.7) 0.66
- Inflammatory diseases 17 (22.1) 5 (15.6) 12 (26.7) 0.25
Clinical Outcomes
Acute kidney injury within 7 days of admission 45 (58.4)
Acute kidney injury severity
- Stage 1 28 (36.3)
- Stage 2 8 (10.3)
- Stage 3 9 (11.7)
Dialysis 9 (11.7) 0 (0) 9 (20.0) 0.007
Hospital mortality 27 (35.1) 9 (28.1) 18 (40.1) 0.28
Composite of mortality or dialysis 31 (40.3) 9 (28.1) 22 (48.9) 0.07
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Table 1 Demographic profiles and clinical characteristics (Continued)
Mechanical ventilation 66 (85.7) 27 (84.4) 39 (86.7) 0.11
Length of mechanical ventilation, h (survivors) n =40 n =19 n =21
44 (26 to 115) 46 (37 to 57) 41 (23 to 234) 0.50
Length of ICU stay, h (survivors) n =50 n =23 n =27
48 (32 to 77) 51 (40 to 73) 47 (19 to 163) 0.51
Length of hospital stay, h (survivors) n =50 n =23 n =27
289 (166 to 409) 289 (194 to 369) 304 (160 to 453) 0.82
Data expressed as mean ± SD, n (%), or median (lower quartile to upper quartile). APACHE II, acute physiological and chronic health evaluation II; CKD, chronic
kidney disease; Comparisons of continuous variables between groups were performed using the independent t-test for parametric data, and the Mann-Whitney
test for non-parametric data (baseline plasma creatinine). Comparisons of categorical data were performed using the Chi-square test.
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without AKI. The baseline creatinine used was the
pre-admission creatinine in 43 patients, 30-day follow-up
creatinine in 18, final creatinine on hospital discharge in
13, and admission creatinine in 3 patients. There was no
difference in source of baseline creatinine between those
with and without AKI. Amongst survivors, there was no
significant difference in the duration of the ICU stay,
hospital stay, or mechanical ventilation between those
with and without AKI. Of 45 AKI patients, 28 were at
severity-stage 1, 8 were stage 2 and 9 were stage 3. A total
of 27 patients (35%) died in hospital and 9 (12%) needed
dialysis: 31 patients (40%) developed the composite
outcome of death or dialysis. The median (interquartile
range) between onset of injury and the first ED sample
was 0.9 h (0.6 h to 1.1 h) and between the first ED sample
and first ICU sample was 1.0 h (0.6 h to 3.2 h).
Biomarker time courses
The temporal profiles of the biomarkers between those
with and without AKI are shown in Figure 2. Key features
are the variation in profiles between patients for all
biomarkers, the greater dynamic range (fold-differences) for
some biomarkers compared to others, and the greater
separation at time points after ED admission (6 to 24 h)
between most AKI and non-AKI patients for urinary
NGAL, and to a lesser extent plasma NGAL and plasma
CysC, compared with other biomarkers. Over the time
period, plasma and urinary CysC, and NGAL, and
urinary GGT and π-GST concentrations were greater
in patients with AKI compared to those without AKI
(repeated-measures ANOVA using log values, P <0.01). In
contrast, there were no differences in urinary α-GST,
AP and albumin between those with and without AKI
(P =0.22, 0.09, and 0.27, respectively).
Diagnosis of AKI
The diagnostic performance of the biomarkers as a
function of time from renal insult is shown in Figure 3.
Plasma NGAL diagnosed AKI at all sampling times. The
performance of other biomarkers varied with time frominsult; urinary NGAL, plasma and urinary CysC diagnosed
AKI within the first 48 h, GGT only between 4 and 12 h,
and π-GST from 8 to 12 h.
Biomarker diagnostic performance on presentation to
the ED was compared with that on admission to the ICU
(Table 2). Plasma CysC and NGAL had similar diagnostic
performance at the two sampling times, whereas urinary
NGAL, CysC and GGT performed better in the ICU than
the ED (P <0.05). Diagnostic performance was poor to fair
(AUC <0.7) in all cases except plasma NGAL, urinary
NGAL and urinary CysC, for which the AUC exceeded
0.7. Urinary π-GST, AP and albumin were not diagnostic
of AKI. α-GST was diagnostic of AKI, but at lower
concentrations (an AUC of 0.32 means 1/α-GST had
an AUC of 0.68).
Sensitivity analysis was conducted excluding patients
who were hypotensive secondary to septic shock, as it
was thought possible that the 14 patients who were
hypotensive secondary to septic shock could have had
an initial insult to the kidney many hours prior to the
hypotensive episode. This sensitivity analysis resulted
in very similar AUCs to those in Table 2 and similar
P-values for the difference in AUC between ED and ICU
entry (data not shown).
Prediction of mortality or dialysis
A multivariate logistic regression model based on variables
measured within the first 24 h was constructed for predic-
tion of mortality or dialysis. This reference model included
variables with P <0.1 on univariate analysis, namely the
presence of AKI24 and the modified APACHE II score
(APACHE II score minus creatinine score, because
creatinine was part of AKI diagnosis). Twenty-six patients
had AKI24. New models were constructed comprising the
reference model variables plus the addition (separately)
of each biomarker. Normalised urinary NGAL and albumin
remained independently predictive of mortality or dialysis
(OR 2.87 (1.32 to 6.26), and 2.72 (1.14 to 6.48), respectively)
(Table 3).
The addition of plasma CysC, normalised urinary NGAL,
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Figure 2 Temporal profiles of acute kidney injury (AKI) biomarker concentrations in patients with and without AKI. For each biomarker
the graph on the right has individual profiles of AKI patients (blue lines) and non-AKI patients (grey lines). The graph on the left represents
median values of AKI patients (blue squares), and non-AKI patients (white circles). Vertical bars cover the interquartile range. The dashed horizontal
lines are pre-specified cut points of biomarkers. P-values are for comparison of biomarker concentrations between those with and without AKI
were performed using repeated-measures analysis of variance after log-transformation. (A) Plasma creatinine; (B) plasma cystatin C; (C) plasma
neutrophil gelatinase-associated lipocalin (NGAL); (D) urinary NGAL; (E) urinary cystatin C; (F) urinary gamma-glutamyltranspeptidase (GGT);
(G) urinary α-glutathione-S-transferase (GST); (H) urinary π-GST; (I) urinary alkaline phosphatase (AP); (J) urinary albumin.
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the largest improvement (total IDI 0.11): addition of urinary
NGAL to the model increased the average calculated risk
(IDIevent) by 0.06 (0.002 to 0.19). The average decrease in
calculated risk (that is, for those who did not die or
needed dialysis, IDInon-event) was 0.04 (0.002 to 0.12).
Urinary albumin, π-GST, and plasma CysC showed
less improvement.
Discussion
Contrary to our hypothesis, earlier biomarker measurement
in the ED did not improve prediction of AKI. Plasmacystatin C and NGAL and urinary NGAL all diagnosed
AKI in the ED and maintained that diagnostic utility for
at least 24 h. Urinary cystatin C and GGT were only
diagnostic in the ICU, and in the case of GGT only
for a short period of time. The urinary concentrations
of GGT, AP, and GST decreased rapidly with little
differentiation between those with and without AKI.
This highlights that these biomarkers are markers of
very early injury, and do not correlate well with
change in glomerular filtration rate (GFR). Indeed, the
main driving forces of their profiles are the reservoir































































































































































































































Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Time dependence of biomarker performance in diagnosis of acute kidney injury (AKI). White circles represent the area under the
receiver operating characteristic curve (AUC) with 95% confidence interval (shaded areas). An AUC with a confidence interval not overlapping 0.5
was considered diagnostic. (A) Plasma creatinine; (B) plasma cystatin C; (C) plasma neutrophil gelatinase-associated lipocalin (NGAL); (D) urinary
NGAL; (E) urinary cystatin C; (F) urinary gamma-glutamyltranspeptidase (GGT); (G) urinary α-glutathione-S-transferase (GST); (H) urinary π-GST;
(I) urinary alkaline phosphatase (AP); (J) urinary albumin.
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similarly with time, although perhaps less rapidly in
patients with AKI. Urinary NGAL and to a lesser
extent, plasma NGAL and CysC, illustrated distinct
elevation in most AKI patients over that of non-AKI
patients during the 24 h following ED presentation.
For plasma CysC, this reflects the loss of GFR and shorter
half-life compared with plasma creatinine. Both plasma
and urinary NGAL concentrations are partly affected
by loss of GFR as well as tubular injury resulting in
upregulation of NGAL and release into both the urine
and plasma [19,20]. The differences in temporal profiles
highlights the importance of choosing the right temporal
window in which to measure these biomarkers. Peak
urinary NGAL and albumin within 24 h of presentation
were independently predictive of mortality after adjustment
for AKI status and illness severity score (APACHE).
A low concentration of urinary α-GST in the ED and
ICU was also diagnostic of AKI. This may reflect that
α-GST was released even more rapidly than the other
biomarkers and was depleted by the time of measurement
in the ED. Urinary GGT, α-GST and π-GST were elevated
in the ED for nearly all patients. Compared to the cut
points for prediction of dialysis need or 30-day mortality
determined from the EARLYARF trial [21] GGT was 2 to
4 times greater, α-GST 100 to 1,000 times greater, and
π-GST 10 to 100 times greater, regardless of whether
subjects had AKI or not, suggesting that these tubular
enzymes are very sensitive to renal hypoperfusion, with
early release even after mild injury. The significance of anTable 2 Emergency Department versus initial ICU performanc
injury diagnosis
Biomarkers Emergency Departmen
Plasma creatinine 0.72 (0.61 to 0.83)
Plasma cystatin C 0.68 (0.56 to 0.80)
Plasma NGAL 0.75 (0.64 to 0.87)
Urinary NGAL 0.68 (0.55 to 0.82)
Urinary cystatin C 0.60 (0.45 to 0.74)
Urinary GGT 0.55 (0.40 to 0.70)
Urinary α-GST 0.32 (0.15 to 0.49)
Urinary π-GST 0.46 (0.28 to 0.65)
Urinary alkaline phosphatase 0.50 (0.35 to 0.65)
Urinary albumin 0.44 (0.29 to 0.59)
Data expressed as area under curve with 95% confidence interval. NGAL, neutrophi
GST, glutathione-S-transferase.increase in tubular enzymes remains to be tested in a
larger patient cohort. As these assays are cheap and
rapidly performed, their utility in detecting a milder form
of injury remains a potential area for exploration.
Albumin excretion was high in patients without AKI,
perhaps because of endothelial dysfunction secondary to
inflammation, a known consequence and independent
predictor of mortality in critically ill patients [22,23].
Albumin remained increased longer in AKI, possibly
due to proximal tubular injury, which reduces albumin
reabsorption [24,25].
Induced, biomarkers such as urinary NGAL, and freely
filtered biomarkers such as CysC, increase following
injury to the proximal and distal tubules. Urinary NGAL
is expressed in the distal tubules and collecting duct.
NGAL expression in the distal tubules is upregulated in
AKI. NGAL is also absorbed into the circulation and
filtered later by the glomerulus [26,27]. Reabsorption of
filtered NGAL along with other low molecular-weight
proteins is impaired in the presence of proximal tubular
injury, further increasing urinary excretion [28,29]. Urinary
CysC is freely filtered in the glomerulus, and similarly
reabsorbed by the proximal tubule. In the presence of
proximal tubule injury, reabsorption of CysC is similarly
impaired, leading to increased urinary excretion [30].
These biomarkers are released early following insult, and
their concentration remains high for a longer duration
[4,31]. Their utility in diagnosis of AKI and prediction of
mortality has been documented in many studies across
different population groups [32-36].e of functional and structural biomarkers in acute kidney
t ICU P-value
0.69 (0.57 to 0.81) 0.15
0.64 (0.52 to 0.77) 0.09
0.80 (0.68 to 0.90) 0.37
0.77 (0.66 to 0.88) 0.04
0.73 (0.61 to 0.85) 0.004
0.69 (0.56 to 0.82) 0.01
0.32 (0.18 to 0.46) 0.79
0.52 (0.37 to 0.67) 0.62
0.57 (0.43 to 0.71) 0.06
0.54 (0.40 to 0.68) 0.08
l gelatinase-associated lipocalin; GGT, gamma-glutamyltranspeptidase;
Table 3 Multivariable logistic regression for biomarker prediction of mortality or dialysis after addition to the
reference model
Peak biomarkers within 24 h (log10)* Beta coefficient Odds ratio (95% CI) P-value
Plasma cystatin C 2.56 12.9 (0.51 to 326) 0.12
Plasma NGAL 0.97 2.62 (0.32 to 21.5) 0.37
Urinary cystatin C/urinary creatinine 0.57 1.77 (0.85 to 3.72) 0.13
Urinary NGAL/urinary creatinine 1.05 2.87 (1.32 to 6.26) 0.008
Urinary alkaline phosphatase/urinary creatinine 0.52 1.68 (0.60 to 4.71) 0.32
Urinary GGT/urinary creatinine 0.46 1.59 (0.52 to 4.81) 0.41
Urinary α-GST/urinary creatinine 0.09 1.10 (0.72 to 1.66) 0.66
Urinary π-GST/urinary creatinine 0.63 1.89 (0.94 to 3.79) 0.07
Urinary albumin/urinary creatinine 1.00 2.72 (1.14 to 6.48) 0.02
*Each biomarker was added separately to the reference model. Urinary biomarkers were normalised to urinary creatinine. The reference model includes variables
with P <0.1 on univariate analysis, namely the modified acute physiological and chronic health evaluation-II score (without creatinine score) and the presence of
AKI24. NGAL, neutrophil gelatinase-associated lipocalin; GGT, gamma-glutamyltranspeptidase; GST, glutathione-S-transferase.
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to injury may result from differences in duration of
decreased kidney perfusion, or the effect of compensatory
mechanisms or intervention. We postulate that a shorter
duration of kidney hypoperfusion will result only in tubular
enzyme release, whereas a longer duration of hypoperfusionTable 4 The integrated discrimination improvement index for
IDI event IDI non-event IDI
Plasma cystatin C 0.02 0.01 0.0
(0.0002 to 0.08) (0.0001 to 0.047) (0.0
Plasma NGAL −0.003 0.01 0.0




(−0.0003 to 0.09) (−0.0002 to 0.06) (−0
Urinary NGAL/urinary creatinine 0.06 0.04 0.1
(0.002 to 0.19) (0.002 to 0.12) (0.0
Urinary AP/urinary creatinine 0.0002 0.0002 (−0.001 to 0.0
(−0.002 to 0.005) 0.003) (−0
Urinary GGT/urinary creatinine 0.003 0.002 0.0
(−0.0006 to 0.04) (−0.0004 to 0.02) (−0
Urinary α-GST/urinary creatinine 0.006 0.004 0.0
(−0.0005 to 0.05) (−0.0003 to 0.03) (−0
Urinary π-GST/urinary creatinine 0.02 0.02 0.0
(0.0001 to 0.11) (0.0001 to 0.07) (0.0
Urinary albumin/urinary creatinine 0.03 0.02 0.0
(0.0006 to 0.12) (0.0006 to 0.080) (0.0
Data expressed with 95% confidence interval. Reference model: acute physiological
of AKI24 both within 24 h of admission. New model: addition of maximal individual
integrated discrimination improvement. IDI event, IDI: improvement in risk predictio
prediction model for no mortality or dialysis; IP, integrated specificity, that is, differe
sensitivity, that is, differences in average sensitivity of reference and new model; NG
GGT, gamma-glutamyltranspeptidase; GST, glutathione-S-transferase.will upregulate the other biomarkers and result in increases
of both tubular enzymes and induced or filtered biomarkers.
This postulate is supported by the longer duration before
return of spontaneous circulation in the sub-cohort of
cardiac arrest patients (n =49) who showed increases in









3 0.55 0.58 0.27 0.27
003 to 0.12) (0.41 to 0.67) (0.42 to 0.69) (0.19 to 0.40) (0.18 to 0.41)
1 0.55 0.56 0.27 0.26
.04 to 0.09) (0.41 to 0.67) (0.39 to 0.68) (0.19 to 0.40) (0.18 to 0.40)
3 0.55 0.58 0.27 0.27
.0005 to 0.15) (0.42 to 0.68) (0.42 to 0.69) (0.19 to 0.40) (0.19 to 0.42)
1 0.55 0.62 0.27 0.24
03 to 0.30) (0.41 to 0.67) (0.45 to 0.76) (0.19 to 0.41) (0.15 to 0.39)
004 0.55 0.56 0.27 0.28
.003 to 0.008) (0.40 to 0.67) (0.39 to 0.67) (0.19 to 0.39) (0.20 to 0.42)
05 0.55 0.56 0.27 0.28
.0009 to 0.06) (0.41 to 0.68) (0.42 to 0.69) (0.19 to 0.41) (0.21 to 0.42)
09 0.55 0.57 0.27 0.28
.0008 to 0.08) (0.40 to 0.67) (0.40 to 0.67) (0.19 to 0.41) (0.20 to 0.42)
4 0.55 0.58 0.27 0.26
002 to 0.17) (0.40 to 0.67) (0.43 to 0.70) (0.19 to 0.41) (0.18 to 0.41)
6 0.55 0.60 0.27 0.25
009 to 0.19) (0.42 to 0.68) (0.44 to 0.71) (0.19 to 0.40) (0.18 to 0.38)
and chronic health evaluation-II score (without creatinine), and the presence
biomarker level within 24 h of admission to the reference model. IDI,
n model for mortality or dialysis; IDI non-event, improvement in risk
nces in average specificity of reference and new model; IS, integrated
AL, neutrophil gelatinase-associated lipocalin; AP, alkaline phopshatase;
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Figure 4 Risk assessment plots showing the additional value of individual biomarkers compared with the reference model for
prediction of the composite of mortality or dialysis. The reference model included the modified acute physiological and chronic health
evaluation (APACHE) II score (without creatinine score), and AKI24 (present or absent). The new models comprised the reference model plus peak
(A) urinary neutrophil gelatinase-associated lipocalin (NGAL), (B) urinary albumin (C) plasma cystatin C, or (D) urinary π-glutathione-S-transferase
(GST) within 24 h. Event curves (squares) are sensitivity versus calculated risk. Non-event curves (circles) are 1-specificity versus calculated risk.
Ralib et al. Critical Care 2014, 18:601 Page 10 of 12
http://ccforum.com/content/18/6/601compared to those with only increased tubular enzymes
(23 ± 13 minutes versus 14 ± 7 minutes, P =0.04). Hence,
patients with increased tubular enzymes and increased
induced or filtered biomarkers may be assumed to have
experienced more severe structural injury, compared to
those with only tubular enzymuria. Nevertheless, the
evaluated biomarkers facilitated in identifying those
with tubular cell injury.
We suggest that because of the inherent limitations
in using plasma creatinine as a gold standard, the
performance of structural biomarkers is best assessedagainst a meaningful clinical outcome, such as mortality or
dialysis. Based on our previous study urinary biomarkers
normalised to urinary creatinine are most likely to be
of prognostic value [10]. Normalised urinary NGAL and
albumin were independently predictive of mortality or
dialysis. A 10-fold increase in urinary NGAL or albumin
increased the odds of mortality or dialysis by approximately
3-fold. Similarly, Siew et al. showed that urinary NGAL was
independently predictive of mortality or dialysis in a study
of 451 critically ill patients [36]. Albuminuria has also been
shown to predict mortality in critically ill patients [22,23].
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http://ccforum.com/content/18/6/601Both urinary NGAL and albumin improved the clinical
model incorporating the APACHE II score and AKI in
the prediction of mortality or dialysis. Plasma CysC, and
urinary π-GST improved the risk prediction model to a
lesser extent than urinary NGAL. Of interest is how
much the improvement of risk assessment is clinically
important. The question remains as to whether the
average increase in risk of 6% identified by addition
of urinary NGAL in those who died or were dialysed
(IDIevent), and the average reduction in risk of 4% in
those who survived or were dialysis-free (IDInon-event),
is sufficient to warrant investment in this additional
test? Will the indication of structural injury to the
kidney change practice? The answer to these questions
will only emerge as clinicians engage with the new
biomarkers, and learn to use them in high-risk cohorts at
the appropriate times.
Study strengths and limitations
Unique aspects of this study were that it (1) examined
critically ill patients at high risk of developing AKI
secondary to significant kidney hypoperfusion; (2)
captured patients very soon after insult; and (3) measured
multiple biomarkers repeatedly from the earliest practic-
able time point following insult. In the 14 patients with
hypotension secondary to septic shock, the onset of sepsis
may have decreased filtration prior to the hypotensive
event recorded as the time of insult. A sensitivity analysis
excluding these patients resulted in only minor differences
to the AUC and no differences in the comparison of the
AUC for any of the biomarkers for the ED versus the ICU.
A lower-than-expected recruitment rate plus interruption
to recruitment due to a major earthquake in Christchurch
meant the final study numbers after 2-years of recruit-
ment were lower than expected (100). This slightly
reduced the power of the study to detect differences in
biomarker performance between the ED and ICU. The
dilution of creatinine is known to change the diagnosis of
AKI in some patients [9,37]. In this analysis we did not
adjust the creatinine for fluid balance. Therefore, as fluid
balance in the ICU is usually positive, the prevalence of
AKI may be overestimated.
Conclusion
Overall in this cohort of patients at high risk of AKI and
with well-documented timing of renal hypoperfusion,
plasma NGAL, CysC and urinary NGAL best diagnosed
AKI in the ED and continued to perform best over 24 h.
The diagnostic performance of six of nine candidate AKI
biomarkers (plasma CysC and NGAL, urinary α-GST,
π-GST, AP and albumin) were equivalent when measured
in the ED or in the ICU. The remaining biomarkers
(urinary NGAL, CysC, and GGT) better diagnosed
AKI at the later time point on entry to the ICU. Theevaluated biomarkers, GGT and AP, facilitated detection
of tubular cell injury in the ED, but without apparent
diagnostic utility. Peak urinary NGAL within 24 h of
admission best predicted the composite outcome of
mortality or dialysis requirement.
Key messages
 AKI injury biomarkers have utility in the ED, but are
optimal a few hours later in the ICU
 Urinary NGAL, plasma NGAL and CysC can help
diagnose AKI in the ED
 The optimum temporal window for urinary NGAL-,
plasma NGAL- and CysC-guided diagnosis is
approximately 6 to 24 h following ED presentation
 Tubular cell injury is evident in the ED in most
patients shortly after renal insult, but poorly predicts
subsequent changes in creatinine
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